Skip to main content
SpringerLink
Log in

Cognitive Enhancers

  • Chapter
  • First Online:
Clinical Psychopharmacology for Neurologists

  • 1033 Accesses

Abstract

Cognitive impairment is a common presenting symptom in a variety of neurologic conditions. This chapter follows the case of a patient who reports a mild decline in cognitive functioning, which gradually progresses to impairments across multiple cognitive domains and interference with daily activities. Treatment options across the spectrum from a mild neurocognitive disorder to the terminal stage of Alzheimer’s disease are discussed. Recommendations regarding treatment initiation with cholinesterase inhibitors, dose titration, combination therapy with memantine, treatment discontinuation, and management of side effects are presented. The role of other therapeutic interventions, such as vitamins, dietary supplements, and lifestyle-based interventions, is also discussed. Finally, a brief survey of the treatment of cognitive impairment in other neurologic disorders, such as multiple sclerosis and Parkinson’s disease dementia, is provided.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Roberts RO, Knopman DS, Mielke MM, Cha RH, Pankratz VS, Christianson TJ, et al. Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. Neurology. 2014;82(4):317–25. https://doi.org/10.1212/WNL.0000000000000055.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Mitchell AJ, Shiri-Feshki M. Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. J Neurol Neurosurg Psychiatry. 2008;79(12):1386–91. https://doi.org/10.1136/jnnp.2007.142679.

    Article  PubMed  CAS  Google Scholar 

  3. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement. 2015;11(6):718–26. https://doi.org/10.1016/j.jalz.2015.05.016.

    Article  PubMed  Google Scholar 

  4. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379–88. https://doi.org/10.1056/NEJMoa050151.

    Article  PubMed  CAS  Google Scholar 

  5. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5(9):e12244. https://doi.org/10.1371/journal.pone.0012244.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Zhang YP, Miao R, Li Q, Wu T, Ma F. Effects of DHA supplementation on hippocampal volume and cognitive function in older adults with mild cognitive impairment: a 12-month randomized, double-blind, placebo-controlled trial. J Alzheimers Dis. 2016;55(2):497–507. https://doi.org/10.3233/JAD-160439.

    Article  CAS  Google Scholar 

  7. Desideri G, Kwik-Uribe C, Grassi D, Necozione S, Ghiadoni L, Mastroiacovo D, et al. Benefits in cognitive function, blood pressure, and insulin resistance through cocoa flavanol consumption in elderly subjects with mild cognitive impairment: the Cocoa, Cognition, and Aging (CoCoA) study. Hypertension. 2012;60(3):794–801. https://doi.org/10.1161/HYPERTENSIONAHA.112.193060.

    Article  PubMed  CAS  Google Scholar 

  8. Suzuki T, Shimada H, Makizako H, Doi T, Yoshida D, Ito K, et al. A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment. PLoS One. 2013;8(4):e61483. https://doi.org/10.1371/journal.pone.0061483.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Vidovich MR, Lautenschlager NT, Flicker L, Clare L, McCaul K, Almeida OP. The PACE study: a randomized clinical trial of cognitive activity strategy training for older people with mild cognitive impairment. Am J Geriatr Psychiatry. 2015;23(4):360–72. https://doi.org/10.1016/j.jagp.2014.04.002.

    Article  PubMed  Google Scholar 

  10. Hajjar I, Hart M, Chen YL, Mack W, Milberg W, Chui H, et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Arch Intern Med. 2012;172(5):442–4. https://doi.org/10.1001/archinternmed.2011.1391.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30(6):1204–15. https://doi.org/10.1038/sj.npp.1300690.

    Article  PubMed  CAS  Google Scholar 

  12. Gomez-Isla T, Blesa R, Boada M, Clarimon J, Del Ser T, Domenech G, et al. A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord. 2008;22(1):21–9. https://doi.org/10.1097/WAD.0b013e3181611024.

    Article  PubMed  CAS  Google Scholar 

  13. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007;6(6):501–12. https://doi.org/10.1016/S1474-4422(07)70109-6.

    Article  PubMed  CAS  Google Scholar 

  14. Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology. 2008;70(22):2024–35. https://doi.org/10.1212/01.wnl.0000303815.69777.26.

    Article  PubMed  CAS  Google Scholar 

  15. Peters O, Lorenz D, Fesche A, Schmidtke K, Hull M, Perneczky R, et al. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. J Nutr Health Aging. 2012;16(6):544–8.

    Article  CAS  PubMed  Google Scholar 

  16. Luchsinger JA, Perez T, Chang H, Mehta P, Steffener J, Pradabhan G, et al. Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial. J Alzheimers Dis. 2016;51(2):501–14. https://doi.org/10.3233/JAD-150493.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev. 2012;9:CD009132. https://doi.org/10.1002/14651858.CD009132.pub2.

    Article  Google Scholar 

  18. Ashby EL, Kehoe PG. Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer’s disease. Expert Opin Investig Drugs. 2013;22(10):1229–42. https://doi.org/10.1517/13543784.2013.812631.

    Article  PubMed  CAS  Google Scholar 

  19. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162(18):2046–52.

    Article  PubMed  Google Scholar 

  20. ADAPT Research Group, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68(21):1800–8. https://doi.org/10.1212/01.wnl.0000260269.93245.d2.

    Article  CAS  Google Scholar 

  21. Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, et al. Extended results of the Alzheimer’s disease anti-inflammatory prevention trial. Alzheimers Dement. 2011;7(4):402–11. https://doi.org/10.1016/j.jalz.2010.12.014.

    Article  PubMed  PubMed Central  Google Scholar 

  22. ADAPT-FS Research Group. Follow-up evaluation of cognitive function in the randomized Alzheimer’s disease anti-inflammatory prevention trial and its follow-up study. Alzheimers Dement. 2015;11(2):216–25 e1. https://doi.org/10.1016/j.jalz.2014.03.009.

    Article  Google Scholar 

  23. Pietri S, Maurelli E, Drieu K, Culcasi M. Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). J Mol Cell Cardiol. 1997;29(2):733–42. https://doi.org/10.1006/jmcc.1996.0316.

    Article  PubMed  CAS  Google Scholar 

  24. Snitz BE, O’Meara ES, Carlson MC, Arnold AM, Ives DG, Rapp SR, et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA. 2009;302(24):2663–70. https://doi.org/10.1001/jama.2009.1913.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300(19):2253–62. https://doi.org/10.1001/jama.2008.683.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012;11(10):851–9. https://doi.org/10.1016/S1474-4422(12)70206-5.

    Article  PubMed  CAS  Google Scholar 

  27. Birks J, Grimley EJ. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2007;2:CD003120. https://doi.org/10.1002/14651858.CD003120.pub2.

    Article  Google Scholar 

  28. de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry. 2012;27(6):592–600. https://doi.org/10.1002/gps.2758.

    Article  PubMed  Google Scholar 

  29. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med. 2002;346(7):476–83. https://doi.org/10.1056/NEJMoa011613.

    Article  PubMed  CAS  Google Scholar 

  30. Clarke R, Bennett D, Parish S, Lewington S, Skeaff M, Eussen SJ, et al. Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. Am J Clin Nutr. 2014;100(2):657–66. https://doi.org/10.3945/ajcn.113.076349.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Kryscio RJ, Abner EL, Schmitt FA, Goodman PJ, Mendiondo M, Caban-Holt A, et al. A randomized controlled Alzheimer’s disease prevention trial’s evolution into an exposure trial: the PREADViSE trial. J Nutr Health Aging. 2013;17(1):72–5. https://doi.org/10.1007/s12603-012-0083-3.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Kryscio RJ, Abner EL, Caban-Holt A, Lovell M, Goodman P, Darke AK, et al. Association of antioxidant supplement use and dementia in the prevention of Alzheimer’s disease by vitamin E and selenium trial (PREADViSE). JAMA Neurol. 2017;74(5):567–73.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol. 2003;60(7):940–6. https://doi.org/10.1001/archneur.60.7.940.

    Article  PubMed  Google Scholar 

  34. Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010;6(6):456–64. https://doi.org/10.1016/j.jalz.2010.01.013.

    Article  PubMed  CAS  Google Scholar 

  35. Dangour AD, Allen E, Elbourne D, Fasey N, Fletcher AE, Hardy P, et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. Am J Clin Nutr. 2010;91(6):1725–32. https://doi.org/10.3945/ajcn.2009.29121.

    Article  PubMed  CAS  Google Scholar 

  36. van de Rest O, Geleijnse JM, Kok FJ, van Staveren WA, Dullemeijer C, Olderikkert MG, et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology. 2008;71(6):430–8. https://doi.org/10.1212/01.wnl.0000324268.45138.86.

    Article  PubMed  CAS  Google Scholar 

  37. Sydenham E, Dangour AD, Lim WS. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev. 2012;6:CD005379. https://doi.org/10.1002/14651858.CD005379.pub3.

    Article  Google Scholar 

  38. Martinez-Lapiscina EH, Clavero P, Toledo E, Estruch R, Salas-Salvado J, San Julian B, et al. Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. J Neurol Neurosurg Psychiatry. 2013;84(12):1318–25. https://doi.org/10.1136/jnnp-2012-304792.

    Article  PubMed  Google Scholar 

  39. Sofi F, Valecchi D, Bacci D, Abbate R, Gensini GF, Casini A, et al. Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. J Intern Med. 2011;269(1):107–17. https://doi.org/10.1111/j.1365-2796.2010.02281.x.

    Article  PubMed  CAS  Google Scholar 

  40. Lautenschlager NT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008;300(9):1027–37. https://doi.org/10.1001/jama.300.9.1027.

    Article  PubMed  CAS  Google Scholar 

  41. Strohle A, Schmidt DK, Schultz F, Fricke N, Staden T, Hellweg R, et al. Drug and exercise treatment of Alzheimer disease and mild cognitive impairment: a systematic review and meta-analysis of effects on cognition in randomized controlled trials. Am J Geriatr Psychiatry. 2015;23(12):1234–49. https://doi.org/10.1016/j.jagp.2015.07.007.

    Article  PubMed  Google Scholar 

  42. Gates N, Fiatarone Singh MA, Sachdev PS, Valenzuela M. The effect of exercise training on cognitive function in older adults with mild cognitive impairment: a meta-analysis of randomized controlled trials. Am J Geriatr Psychiatry. 2013;21(11):1086–97. https://doi.org/10.1016/j.jagp.2013.02.018.

    Article  PubMed  Google Scholar 

  43. Sungkarat S, Boripuntakul S, Chattipakorn N, Watcharasaksilp K, Lord SR. Effects of tai chi on cognition and fall risk in older adults with mild cognitive impairment: a randomized controlled trial. J Am Geriatr Soc. 2016. https://doi.org/10.1111/jgs.14594.

  44. Lee KS, Lee Y, Back JH, Son SJ, Choi SH, Chung YK, et al. Effects of a multidomain lifestyle modification on cognitive function in older adults: an eighteen-month community-based cluster randomized controlled trial. Psychother Psychosom. 2014;83(5):270–8. https://doi.org/10.1159/000360820.

    Article  PubMed  Google Scholar 

  45. Han JW, Lee H, Hong JW, Kim K, Kim T, Byun HJ, et al. Multimodal cognitive enhancement therapy for patients with mild cognitive impairment and mild dementia: a multi- center, randomized, controlled, double-blind. Crossover Trial J Alzheimers Dis. 2016;55(2):787–96. https://doi.org/10.3233/JAD-160619.

    Article  Google Scholar 

  46. Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–63. https://doi.org/10.1016/S0140-6736(15)60461-5.

    Article  PubMed  Google Scholar 

  47. Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues JF, et al. Mapt study: a multidomain approach for preventing Alzheimer’s disease: design and baseline data. J Prev Alzheimers Dis. 2014;1(1):13–22.

    PubMed  PubMed Central  CAS  Google Scholar 

  48. Kivipelto M, Vellas B. Non-pharmacological intervention in populations at high risk of AD dementia: results of the MAPT and LipiDiDiet studies. Symposium 2, Clinical Trials on Alzheimer’s Disease 9th Annual Meeting. San Diego; 2016.

    Google Scholar 

  49. Moll van Charante EP, Richard E, Eurelings LS, van Dalen JW, Ligthart SA, van Bussel EF, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet. 2016;388(10046):797–805. https://doi.org/10.1016/S0140-6736(16)30950-3.

    Article  PubMed  Google Scholar 

  50. Schneider LS. Reduce vascular risk to prevent dementia? Lancet. 2016;388(10046):738–40. https://doi.org/10.1016/S0140-6736(16)31129-1.

    Article  PubMed  Google Scholar 

  51. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD005593. https://doi.org/10.1002/14651858.cd005593.

    Article  Google Scholar 

  52. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2004;75(5):677–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;41(2):615–31. https://doi.org/10.3233/JAD-132690.

    Article  PubMed  CAS  Google Scholar 

  54. Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand SL, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009;169(9):867–73. https://doi.org/10.1001/archinternmed.2009.43.

    Article  PubMed  Google Scholar 

  55. Park-Wyllie LY, Mamdani MM, Li P, Gill SS, Laupacis A, Juurlink DN. Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study. PLoS Med. 2009;6(9):e1000157. https://doi.org/10.1371/journal.pmed.1000157.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc. 2011;59(6):1019–31. https://doi.org/10.1111/j.1532-5415.2011.03450.x.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Sheffrin M, Miao Y, Boscardin WJ, Steinman MA. Weight loss associated with cholinesterase inhibitors in individuals with dementia in a national healthcare system. J Am Geriatr Soc. 2015;63(8):1512–8. https://doi.org/10.1111/jgs.13511.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Lai EC, Wong MB, Iwata I, Zhang Y, Hsieh CY, Kao Yang YH, et al. Risk of pneumonia in new users of cholinesterase inhibitors for dementia. J Am Geriatr Soc. 2015;63(5):869–76. https://doi.org/10.1111/jgs.13380.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Lampela P, Tolppanen AM, Tanskanen A, Tiihonen J, Lavikainen P, Hartikainen S, et al. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer’s disease. Ann Med. 2016:1–10. https://doi.org/10.1080/07853890.2016.1254349.

  60. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD001190. https://doi.org/10.1002/14651858.CD001190.pub2.

    Article  Google Scholar 

  61. Birks JS, Chong LY, Grimley EJ. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev. 2015;9:CD001191. https://doi.org/10.1002/14651858.CD001191.pub4.

    Article  PubMed  Google Scholar 

  62. Nieto RA, Deardorff WJ, Grossberg GT. Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer’s disease. Expert Opin Pharmacother. 2016;17(6):861–70. https://doi.org/10.1517/14656566.2016.1159296.

    Article  PubMed  CAS  Google Scholar 

  63. Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007;69(4 Suppl 1):S14–22. https://doi.org/10.1212/01.wnl.0000281847.17519.e0.

    Article  PubMed  CAS  Google Scholar 

  64. Lovborg H, Jonsson AK, Hagg S. A fatal outcome after unintentional overdosing of rivastigmine patches. Curr Drug Saf. 2012;7(1):30–2.

    Article  PubMed  Google Scholar 

  65. Important Drug Warning. U.S. Food and Drug Administration. 2010. http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/UCM226090.pdf. Accessed 1 Dec 2016.

  66. Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, et al. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease. Neuropsychiatr Dis Treat. 2014;10:391–401. https://doi.org/10.2147/ndt.s57909.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  67. Aronson S, Van Baelen B, Kavanagh S, Schwalen S. Optimal dosing of galantamine in patients with mild or moderate Alzheimer’s disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial. Drugs Aging. 2009;26(3):231–9. https://doi.org/10.2165/00002512-200926030-00004.

    Article  PubMed  CAS  Google Scholar 

  68. Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer’s disease. Dement Geriatr Cogn Disord. 2005;20(2–3):120–32. https://doi.org/10.1159/000086613.

    Article  PubMed  CAS  Google Scholar 

  69. Seltzer B. Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease. Clin Interv Aging. 2010;5:1–6.

    PubMed  PubMed Central  CAS  Google Scholar 

  70. Emre M. Switching cholinesterase inhibitors in patients with Alzheimer’s disease. Int J Clin Pract Suppl. 2002;127:64–72.

    CAS  Google Scholar 

  71. Cagnin A, Cester A, Costa B, Ermani M, Gabelli C, Gambina G, et al. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer’s disease. Neurol Sci. 2015;36(3):457–63. https://doi.org/10.1007/s10072-014-2002-3.

    Article  PubMed  Google Scholar 

  72. Auriacombe S, Pere JJ, Loria-Kanza Y, Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil. Curr Med Res Opin. 2002;18(3):129–38. https://doi.org/10.1185/030079902125000471.

    Article  PubMed  CAS  Google Scholar 

  73. Massoud F, Desmarais JE, Gauthier S. Switching cholinesterase inhibitors in older adults with dementia. Int Psychogeriatr. 2011;23(3):372–8. https://doi.org/10.1017/s1041610210001985.

    Article  PubMed  Google Scholar 

  74. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT, Group MM-M-S. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83–9.

    Article  CAS  PubMed  Google Scholar 

  75. Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol. 2011;68(8):991–8. https://doi.org/10.1001/archneurol.2011.69.

    Article  PubMed  Google Scholar 

  76. Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014;311(1):33–44. https://doi.org/10.1001/jama.2013.282834.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med. 1997;336(17):1216–22. https://doi.org/10.1056/NEJM199704243361704.

    Article  PubMed  CAS  Google Scholar 

  78. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37–46.

    Article  CAS  PubMed  Google Scholar 

  79. Abner EL, Schmitt FA, Mendiondo MS, Marcum JL, Kryscio RJ. Vitamin E and all-cause mortality: a meta-analysis. Curr Aging Sci. 2011;4(2):158–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Kim JM, White RH. Effect of vitamin E on the anticoagulant response to warfarin. Am J Cardiol. 1996;77(7):545–6.

    Article  CAS  PubMed  Google Scholar 

  81. Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011;77(6):556–63. https://doi.org/10.1212/WNL.0b013e318228bf11.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74(12):956–64. https://doi.org/10.1212/WNL.0b013e3181d6476a.

    Article  PubMed  CAS  Google Scholar 

  83. Yang G, Wang Y, Sun J, Zhang K, Liu J. Ginkgo biloba for mild cognitive impairment and Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials. Curr Top Med Chem. 2016;16(5):520–8.

    Article  CAS  PubMed  Google Scholar 

  84. Jiang L, Su L, Cui H, Ren J, Li C. Ginkgo biloba extract for dementia: a systematic review. Shanghai Arch Psychiatry. 2013;25(1):10–21. https://doi.org/10.3969/j.issn.1002-0829.2013.01.005.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Hashiguchi M, Ohta Y, Shimizu M, Maruyama J, Mochizuki M. Meta-analysis of the efficacy and safety of Ginkgo biloba extract for the treatment of dementia. J Pharm Health Care Sci. 2015;1:14. https://doi.org/10.1186/s40780-015-0014-7.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Tan MS, Yu JT, Tan CC, Wang HF, Meng XF, Wang C, et al. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2015;43(2):589–603. https://doi.org/10.3233/JAD-140837.

    Article  PubMed  CAS  Google Scholar 

  87. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010;304(17):1903–11. https://doi.org/10.1001/jama.2010.1510.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  88. Mazereeuw G, Lanctot KL, Chau SA, Swardfager W, Herrmann N. Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. Neurobiol Aging. 2012;33(7):1482. e17-29. https://doi.org/10.1016/j.neurobiolaging.2011.12.014.

    Article  PubMed  CAS  Google Scholar 

  89. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. 2006;63(10):1402–8. https://doi.org/10.1001/archneur.63.10.1402.

    Article  PubMed  Google Scholar 

  90. Burckhardt M, Herke M, Wustmann T, Watzke S, Langer G, Fink A. Omega-3 fatty acids for the treatment of dementia. Cochrane Database Syst Rev. 2016;4:CD009002. https://doi.org/10.1002/14651858.CD009002.pub3.

    Article  PubMed  Google Scholar 

  91. Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011;76(16):1389–94. https://doi.org/10.1212/WNL.0b013e318216eb7b.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  92. Laver K, Dyer S, Whitehead C, Clemson L, Crotty M. Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews. BMJ Open. 2016;6(4):e010767. https://doi.org/10.1136/bmjopen-2015-010767.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Van’t Leven N, Prick AE, Groenewoud JG, Roelofs PD, de Lange J, Pot AM. Dyadic interventions for community-dwelling people with dementia and their family caregivers: a systematic review. Int Psychogeriatr. 2013;25(10):1581–603. https://doi.org/10.1017/S1041610213000860.

    Article  Google Scholar 

  94. Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139(9):1136–9. https://doi.org/10.1176/ajp.139.9.1136.

    Article  PubMed  CAS  Google Scholar 

  95. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4.

    Article  CAS  PubMed  Google Scholar 

  96. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: a 24-week, randomized, double-blind study. Clin Ther. 2010;32(7):1234–51. https://doi.org/10.1016/j.clinthera.2010.06.019.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  97. Statistical review(s). Donepezil 23 mg tablets drug approval package. U.S. Food and Drug Administration. 2010. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000StatR.pdf. Accessed 1 Dec 2016.

  98. Medical review(s). Donepezil 23 mg tablets drug approval package. U.S. Food and Drug Administration. 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf. Accessed 1 Dec 2016.

  99. Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P. High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer’s disease: drug profile and clinical guidelines. CNS Neurosci Ther. 2013;19(5):294–301. https://doi.org/10.1111/cns.12076.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  100. Farlow M, Veloso F, Moline M, Yardley J, Brand-Schieber E, Bibbiani F, et al. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease. BMC Neurol. 2011;11:57. https://doi.org/10.1186/1471-2377-11-57.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  101. Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm(2)) in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012;33(5):341–53. https://doi.org/10.1159/000340056.

    Article  PubMed  CAS  Google Scholar 

  102. Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Somogyi M. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer’s dementia. CNS Neurosci Ther. 2013;19(10):745–52. https://doi.org/10.1111/cns.12158.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  103. Winblad B, Jones RW, Wirth Y, Stöffler A, Möbius HJ. Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord. 2007;24(1):20–7. https://doi.org/10.1159/000102568.

    Article  PubMed  CAS  Google Scholar 

  104. Rive B, Gauthier S, Costello S, Marre C, Francois C. Synthesis and comparison of the meta-analyses evaluating the efficacy of memantine in moderate to severe stages of Alzheimer’s disease. CNS Drugs. 2013;27(7):573–82. https://doi.org/10.1007/s40263-013-0074-x.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  105. Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer’s disease: a systematic review. BMJ Open. 2012;2(3):e000917. https://doi.org/10.1136/bmjopen-2012-000917.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Matsunaga S, Kishi T, Iwata N. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer’s disease: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2014. https://doi.org/10.1093/ijnp/pyu115.

  107. Schmidt R, Hofer E, Bouwman FH, Buerger K, Cordonnier C, Fladby T, et al. EFNS-ENS/EAN guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol. 2015;22(6):889–98. https://doi.org/10.1111/ene.12707.

    Article  PubMed  CAS  Google Scholar 

  108. Atri A, Hendrix SB, Pejovic V, Hofbauer RK, Edwards J, Molinuevo JL, et al. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis. Alzheimers Res Ther. 2015;7(1):28. https://doi.org/10.1186/s13195-015-0109-2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  109. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev. 2003;9(3):275–308.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Deardorff WJ, Grossberg GT. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease. Drug Des Devel Ther. 2016;10:3267–79. https://doi.org/10.2147/DDDT.S86463.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  111. Rountree SD, Atri A, Lopez OL, Doody RS. Effectiveness of antidementia drugs in delaying Alzheimer’s disease progression. Alzheimers Dement. 2013;9(3):338–45. https://doi.org/10.1016/j.jalz.2012.01.002.

    Article  PubMed  Google Scholar 

  112. Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther. 2009;1(2):7. https://doi.org/10.1186/alzrt7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  113. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22(3):209–21. https://doi.org/10.1097/WAD.0b013e31816653bc.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  114. Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(6):600–7. https://doi.org/10.1136/jnnp.2008.158964.

    Article  PubMed  CAS  Google Scholar 

  115. Parsons C. Withdrawal of antidementia drugs in older people: who, when and how? Drugs Aging. 2016;33(8):545–56. https://doi.org/10.1007/s40266-016-0384-z.

    Article  PubMed  CAS  Google Scholar 

  116. O'Regan J, Lanctot KL, Mazereeuw G, Herrmann N. Cholinesterase inhibitor discontinuation in patients with Alzheimer’s disease: a meta-analysis of randomized controlled trials. J Clin Psychiatry. 2015;76(11):e1424–31. https://doi.org/10.4088/JCP.14r09237.

    Article  PubMed  Google Scholar 

  117. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366(10):893–903. https://doi.org/10.1056/NEJMoa1106668.

    Article  PubMed  CAS  Google Scholar 

  118. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Nursing home placement in the donepezil and memantine in moderate to severe Alzheimer’s disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurol. 2015;14(12):1171–81. https://doi.org/10.1016/S1474-4422(15)00258-6.

    Article  PubMed  Google Scholar 

  119. Herrmann N, O’Regan J, Ruthirakuhan M, Kiss A, Eryavec G, Williams E, et al. A randomized placebo-controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease. J Am Med Dir Assoc. 2016;17(2):142–7. https://doi.org/10.1016/j.jamda.2015.08.019.

    Article  PubMed  Google Scholar 

  120. O’Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698–706. https://doi.org/10.1016/S0140-6736(15)00463-8.

    Article  PubMed  Google Scholar 

  121. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6(9):782–92. https://doi.org/10.1016/S1474-4422(07)70195-3.

    Article  PubMed  CAS  Google Scholar 

  122. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359(9314):1283–90. https://doi.org/10.1016/S0140-6736(02)08267-3.

    Article  PubMed  Google Scholar 

  123. Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21(14):931–7.

    Article  CAS  PubMed  Google Scholar 

  124. Kishi T, Matsunaga S, Iwata N. Memantine for the treatment of frontotemporal dementia: a meta-analysis. Neuropsychiatr Dis Treat. 2015;11:2883–5. https://doi.org/10.2147/NDT.S94430.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  125. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031–6. https://doi.org/10.1016/S0140-6736(00)03399-7.

    Article  PubMed  CAS  Google Scholar 

  126. Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015;172(8):731–42. https://doi.org/10.1176/appi.ajp.2015.14121582.

    Article  PubMed  Google Scholar 

  127. Matsunaga S, Kishi T, Iwata N. Memantine for Lewy body disorders: systematic review and meta-analysis. Am J Geriatr Psychiatry. 2015;23(4):373–83. https://doi.org/10.1016/j.jagp.2013.11.007.

    Article  PubMed  Google Scholar 

  128. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2509–18. https://doi.org/10.1056/NEJMoa041470.

    Article  PubMed  CAS  Google Scholar 

  129. Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–77. https://doi.org/10.1016/S1474-4422(10)70194-0.

    Article  PubMed  CAS  Google Scholar 

  130. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613–8. https://doi.org/10.1016/S1474-4422(09)70146-2.

    Article  PubMed  CAS  Google Scholar 

  131. Sanmarti M, Ibanez L, Huertas S, Badenes D, Dalmau D, Slevin M, et al. HIV-associated neurocognitive disorders. J Mol Psychiatry. 2014;2(1):2. https://doi.org/10.1186/2049-9256-2-2.

    Article  PubMed  PubMed Central  Google Scholar 

  132. Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007;21(14):1877–86. https://doi.org/10.1097/QAD.0b013e32813384e8.

    Article  PubMed  CAS  Google Scholar 

  133. Sacktor N, Miyahara S, Deng L, Evans S, Schifitto G, Cohen BA, et al. Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology. 2011;77(12):1135–42. https://doi.org/10.1212/WNL.0b013e31822f0412.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  134. Schifitto G, Zhang J, Evans SR, Sacktor N, Simpson D, Millar LL, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology. 2007;69(13):1314–21. https://doi.org/10.1212/01.wnl.0000268487.78753.0f.

    Article  PubMed  CAS  Google Scholar 

  135. Sesok S, Bolle N, Kobal J, Bucik V, Vodusek DB. Cognitive function in early clinical phase huntington disease after rivastigmine treatment. Psychiatr Danub. 2014;26(3):239–48.

    PubMed  CAS  Google Scholar 

  136. Cubo E, Shannon KM, Tracy D, Jaglin JA, Bernard BA, Wuu J, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006;67(7):1268–71. https://doi.org/10.1212/01.wnl.0000238106.10423.00.

    Article  PubMed  CAS  Google Scholar 

  137. Patti F. Treatment of cognitive impairment in patients with multiple sclerosis. Expert Opin Investig Drugs. 2012;21(11):1679–99. https://doi.org/10.1517/13543784.2012.716036.

    Article  PubMed  CAS  Google Scholar 

  138. He D, Zhang Y, Dong S, Wang D, Gao X, Zhou H. Pharmacological treatment for memory disorder in multiple sclerosis. Cochrane Database Syst Rev. 2013;12:CD008876. https://doi.org/10.1002/14651858.CD008876.pub3.

    Article  Google Scholar 

  139. Rosti-Otajarvi EM, Hamalainen PI. Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Syst Rev. 2014;2:CD009131. https://doi.org/10.1002/14651858.CD009131.pub3.

    Article  Google Scholar 

  140. Bortolato B, Miskowiak KW, Kohler CA, Maes M, Fernandes BS, Berk M, et al. Cognitive remission: a novel objective for the treatment of major depression? BMC Med. 2016;14:9. https://doi.org/10.1186/s12916-016-0560-3.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  141. Rosenblat JD, Kakar R, McIntyre RS. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Int J Neuropsychopharmacol. 2015;19(2). https://doi.org/10.1093/ijnp/pyv082.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Holtzheimer PE 3rd, Meeks TW, Kelley ME, Mufti M, Young R, McWhorter K, et al. A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. Int J Geriatr Psychiatry. 2008;23(6):625–31. https://doi.org/10.1002/gps.1951.

    Article  PubMed  PubMed Central  Google Scholar 

  143. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007;164(10):1593–602. https://doi.org/10.1176/appi.ajp.2007.06081358.

    Article  PubMed  Google Scholar 

  144. Freudenreich O, Herz L, Deckersbach T, Evins AE, Henderson DC, Cather C, et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology. 2005;181(2):358–63. https://doi.org/10.1007/s00213-005-2235-1.

    Article  PubMed  CAS  Google Scholar 

  145. Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM, et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry. 2008;165(1):82–9. https://doi.org/10.1176/appi.ajp.2007.07050724.

    Article  PubMed  Google Scholar 

  146. Kishi T, Iwata N. NMDA receptor antagonists interventions in schizophrenia: meta-analysis of randomized, placebo-controlled trials. J Psychiatr Res. 2013;47(9):1143–9. https://doi.org/10.1016/j.jpsychires.2013.04.013.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Behavioral Neuroscience, Saint Louis University School of Medicine, St. Louis, MO, USA

    William James Deardorff MD

  2. Division of Geriatric Psychiatry, Department of Psychiatry & Behavioral Neuroscience, St. Louis University School of Medicine, St. Louis, MO, USA

    George T. Grossberg MD

Authors
  1. William James Deardorff MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George T. Grossberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William James Deardorff MD .

Editor information

Editors and Affiliations

  1. Professor & Director, Division of Geriatric Psychiatry, Department of Psychiatry & Behavioral Neuroscience, St. Louis University School of Medicine, St. Louis, Missouri, USA

    George T. Grossberg

  2. Co-Director of Neurology, SSM Neuroscience Institute, St. Louis, Missouri, USA

    Laurence J. Kinsella

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Deardorff, W.J., Grossberg, G.T. (2018). Cognitive Enhancers. In: Grossberg, G., Kinsella, L. (eds) Clinical Psychopharmacology for Neurologists. Springer, Cham. https://doi.org/10.1007/978-3-319-74604-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-74604-3_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-74602-9

  • Online ISBN: 978-3-319-74604-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation